Home
BIIB
BIIB News

Latest Biogen Inc. (BIIB) News on November 23, 2025

MT Newswires

2 days ago

Piper Sandler Adjusts Price Target on Biogen to $157 From $118, Maintains Neutral Rating

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

GlobeNewswire

3 days ago

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.

Barrons.com

3 days ago

Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.

A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results

Simply Wall St.

4 days ago

A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results

Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion

GlobeNewswire

4 days ago

Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion

Biogen Stock: Is Wall Street Bullish or Bearish?

Barchart

5 days ago

Biogen Stock: Is Wall Street Bullish or Bearish?

MT Newswires

6 days ago

Biogen Says EU Committee Recommends Approval of High Dose Nusinersen Regimen

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

GlobeNewswire

6 days ago

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Business Wire

6 days ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Biogen acquires Alcyone to boost CNS drug delivery

Medical Device Network

6 days ago

Biogen acquires Alcyone to boost CNS drug delivery

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

GlobeNewswire

6 days ago

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

MT Newswires

8 days ago

Biogen Completes Acquisition of Alcyone Therapeutics

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

GlobeNewswire

9 days ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period (2025-2034) Amid Advances in Diagnostics and Targeted Therapies | DelveInsight

PR Newswire

11 days ago

Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period (2025-2034) Amid Advances in Diagnostics and Targeted Therapies | DelveInsight

MT Newswires

23 days ago

Wells Fargo Adjusts Price Target on Biogen to $155 From $140

MT Newswires

23 days ago

Baird Adjusts Price Target on Biogen to $250 From $255

Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative

Simply Wall St.

23 days ago

Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative

MT Newswires

23 days ago

RBC Cuts Price Target on Biogen to $210 From $217, Keeps Outperform Rating

Biogen (BIIB) Valuation: Exploring the Discount as Investor Sentiment Shifts

Simply Wall St.

23 days ago

Biogen (BIIB) Valuation: Exploring the Discount as Investor Sentiment Shifts

Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ...

GuruFocus.com

23 days ago

Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ...

Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem

Investor's Business Daily

23 days ago

Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem

BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View

Zacks

23 days ago

BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View

Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight

PR Newswire

a month ago

Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

GlobeNewswire

a month ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

GlobeNewswire

a month ago

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis

Zacks

a month ago

Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis

IMPALA Appoints Ann Marie Dunne as New Chair, Succeeding Jonathan Taylor

GlobeNewswire

a month ago

IMPALA Appoints Ann Marie Dunne as New Chair, Succeeding Jonathan Taylor

MT Newswires

a month ago

Wedbush Raises Price Target on Biogen to $135 From $129, Keeps Neutral Rating

1 Healthcare Stock to Research Further and 2 We Find Risky

StockStory

a month ago

1 Healthcare Stock to Research Further and 2 We Find Risky

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

GlobeNewswire

a month ago

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

Biogen (BIIB): Revisiting Valuation After Recent Pipeline and Partnership Developments

Simply Wall St.

a month ago

Biogen (BIIB): Revisiting Valuation After Recent Pipeline and Partnership Developments

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

StockStory

a month ago

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

Zacks

a month ago

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

PR Newswire

a month ago

Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

MT Newswires

a month ago

Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome

Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength?

Simply Wall St.

2 months ago

Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength?

3 Low-Volatility Stocks That Concern Us

StockStory

2 months ago

3 Low-Volatility Stocks That Concern Us

Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT

Insider Monkey

2 months ago

Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT

S&P 500, Dow Reach New Peaks as Traders Look Past Ongoing Shutdown

MT Newswires

2 months ago

S&P 500, Dow Reach New Peaks as Traders Look Past Ongoing Shutdown

Drug Stock Rally Helps Push Dow and S&P 500 to Records

The Wall Street Journal

2 months ago

Drug Stock Rally Helps Push Dow and S&P 500 to Records

MT Newswires

2 months ago

US Equity Indexes Rise as Healthcare Jumps, October Rate-Cut Certainty Increases Amid Surprise Fall in Private Payrolls

MT Newswires

2 months ago

Healthcare Helps Lift US Equity Indexes After Federal Shutdown Begins

Equities Rise Intraday as Markets Look Past Shutdown

MT Newswires

2 months ago

Equities Rise Intraday as Markets Look Past Shutdown

MT Newswires

2 months ago

Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

GlobeNewswire

2 months ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

MT Newswires

2 months ago

Biogen Says US FDA Delays Approval of Spinal Muscular Atrophy Treatment

US FDA declines to approve higher dose of Biogen's genetic disorder drug

Reuters

2 months ago

US FDA declines to approve higher dose of Biogen's genetic disorder drug

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

GlobeNewswire

2 months ago

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

Biogen Gets EU Nod for First Postpartum Depression Drug

Zacks

2 months ago

Biogen Gets EU Nod for First Postpartum Depression Drug

MT Newswires

2 months ago

Biogen to Acquire Alcyone Therapeutics for Initial $85 million

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

GlobeNewswire

2 months ago

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Biogen’s Zurzuvae approved as first postpartum depression drug in Europe

Pharmaceutical Technology

2 months ago

Biogen’s Zurzuvae approved as first postpartum depression drug in Europe

Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs

BioPharma Dive

2 months ago

Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs

MT Newswires

2 months ago

Biogen Gets EU Approval for Postpartum Depression Treatment

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

GlobeNewswire

2 months ago

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way

StockStory

2 months ago

Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way

Canaccord Genuity Reiterates a Buy on Biogen (BIIB)

Insider Monkey

2 months ago

Canaccord Genuity Reiterates a Buy on Biogen (BIIB)

Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?

Simply Wall St.

2 months ago

Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?

H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects

Insider Monkey

2 months ago

H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects

Is Biogen Stock Underperforming the Nasdaq?

Barchart

2 months ago

Is Biogen Stock Underperforming the Nasdaq?

MT Newswires

2 months ago

Piper Sandler Adjusts Price Target on Biogen to $118 From $115, Maintains Neutral Rating

Argus Research

2 months ago

Weekly Stock List

Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates

Simply Wall St.

3 months ago

Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates

Biogen (BIIB) Stock Trades Down, Here Is Why

StockStory

3 months ago

Biogen (BIIB) Stock Trades Down, Here Is Why

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Insider Monkey

3 months ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

MT Newswires

3 months ago

C4 Therapeutics Says Biogen's IND Application Accepted by FDA to Treat Autoimmune Diseases

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

GlobeNewswire

3 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

GlobeNewswire

3 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

MT Newswires

3 months ago

US Equity Indexes Decline as Gains in Treasury Yields Push Mag-7 Lower

MT Newswires

3 months ago

US Equity Markets End Lower Following Court Ruling Against Trump Tariffs

Stock Market Today: Dow Dives 500 Points On Trump Tariff News; Nvidia, Palantir Sell Off (Live Coverage)

Investor's Business Daily

3 months ago

Stock Market Today: Dow Dives 500 Points On Trump Tariff News; Nvidia, Palantir Sell Off (Live Coverage)

Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer

GlobeNewswire

3 months ago

Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer

These Stocks Are Moving the Most Today: Nvidia, PepsiCo, NIO, Biogen, Newmont, Signet, and More

Barrons.com

3 months ago

These Stocks Are Moving the Most Today: Nvidia, PepsiCo, NIO, Biogen, Newmont, Signet, and More

MT Newswires

3 months ago

Stoke Therapeutics, Biogen Say Studies Support Potential of Dravet Syndrome Treatment

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Business Wire

3 months ago

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

GlobeNewswire

3 months ago

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries

Insider Monkey

3 months ago

Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries

Startup Corsera Health aims to bring preventive heart medicine to the masses

BioPharma Dive

3 months ago

Startup Corsera Health aims to bring preventive heart medicine to the masses

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment

Investor's Business Daily

3 months ago

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

PR Newswire

3 months ago

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

MT Newswires

3 months ago

Biogen's Postnatal Depression Drug Zuranolone Gets UK Approval

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Business Wire

3 months ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

GlobeNewswire

3 months ago

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

MT Newswires

3 months ago

Biogen, Eisai Launch Alzheimer's Disease Treatment in Austria; Germany to Follow

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

GlobeNewswire

3 months ago

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

Morningstar Research

3 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

GlobeNewswire

3 months ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Biogen Stock: Analyst Estimates & Ratings

Barchart

3 months ago

Biogen Stock: Analyst Estimates & Ratings

2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore

StockStory

3 months ago

2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

Business Wire

3 months ago

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials

TipRanks

5 months ago

Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results

Insider Monkey

5 months ago

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results

MT Newswires

5 months ago

Biogen Reports Mobility Gains with New Nusinersen Dose for Spinal Disorder

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

GlobeNewswire

5 months ago

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

MT Newswires

5 months ago

Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says

5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call

StockStory

5 months ago

5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call

Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations

Insider Monkey

5 months ago

Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations

Can Biogen Save Even More Kids With This New Drug?

Investor's Business Daily

5 months ago

Can Biogen Save Even More Kids With This New Drug?

Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics

GlobeNewswire

5 months ago

Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics

MT Newswires

5 months ago

Biogen to Advance Investigational Spinal Muscular Atrophy Therapy to Registrational Studies

Share on Social Networks: